Healthy adolescents aged 15–19 years are recommended to receive MenACWY vaccine

Healthy adolescents aged 15–19 years are recommended to receive a single dose of any MenACWY vaccine.

MenACWY vaccine is funded through the NIP for all adolescents aged 14-16 years. For details see the National Immunisation Program Schedule.

There is no preference for brand of MenACWY vaccine - MenQuadfi, Menveo or Nimenrix – for adolescents aged 15-19 years.

Healthy adolescents who have received the MenACWY vaccine in the past should receive a dose of MenACWY vaccine after they turn 14 years of age. 

Healthy adolescents who have received a dose of quadrivalent meningococcal polysaccharide vaccine in the past (4vMenPV — likely overseas as discontinued in Australia for some time) should receive a dose of conjugate MenACWY vaccine at age 15–19 years. MenACWY vaccine should be given at least 6 months after the dose of 4vMenPV.